Home › All Companies › ACBM

ACRO BIOMEDICAL CO., LTD. (ACBM)

AI-Powered SEC Filing Analysis

Annual Report Filed: 2026-02-11

Key Insights

  • The company has reported no revenue and no profits for the past 3 years, indicating a lack of commercial success for its products.
  • The company's lease agreements in Hong Kong suggest it may be focused on international expansion, but this strategy has not yet translated to financial results.
  • The CEO and minority shareholders have maintained control of the company, with little evidence of outside investment or change in ownership structure.
Sentiment: Negative Significance: 7/10
View Original Filing →
Current Report Filed: 2026-01-08

Key Insights

  • Acro Biomedical dismissed its previous auditor KCCW Accountancy Corp. and appointed Weinberg & Company as its new independent registered accounting firm.
  • There were no disagreements between the company and the previous auditor KCCW on any accounting, financial reporting, or audit-related matters.
  • The previous auditor's report contained an explanatory paragraph regarding uncertainty about the company's ability to continue as a going concern.
Sentiment: Neutral Significance: 4/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.